Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
chronic obstructive pulmonary disease (COPD)
Biotech
AstraZeneca’s faith in IL-33 blocker pays off with new ph. 3 win
AstraZeneca’s COPD candidate has served up a third phase 3 win, offering further evidence the Big Pharma may have cracked the anti-IL-33 code.
James Waldron
Apr 20, 2026 7:22am
Connect’s Dupixent rival hits the mark in phase 3 eczema trial
Mar 30, 2026 9:32am
AstraZeneca’s COPD hits breathe life into class rocked by flops
Mar 27, 2026 5:58am
Sanofi backs Altesa's $75M series B to bankroll rhinovirus study
Feb 19, 2026 7:00am
AirNexis swoops in with $200M series A for COPD asset
Jan 9, 2026 11:01am
GSK pens $750M deal for COPD-focused oligonucleotide in phase 1
Oct 28, 2025 6:45am
